Valneva SE (VALN) EBIT Margin (2021 - 2026)
Valneva SE (VALN) posted quarterly EBIT Margin of 76.68% for Q1 2026, down 6457.0% year-on-year from 1.21% in Q1 2025, and down 5.0% on a QoQ basis from 73.03% in Q4 2025.
Valneva SE (VALN) EBIT Margin (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported EBIT Margin for 6 consecutive years, with 76.68% the latest figure, recorded in Q1 2026.
- Quarterly EBIT Margin fell 6457.0% year-over-year to 76.68% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 71.5% (down 3766.0% YoY) and the FY2025 annual result came in at 51.97%, down 6013.0% from the prior year.
- EBIT Margin slipped to 76.68% in Q1 2026 per VALN's latest filing, from 73.03% in the prior quarter.
- Over the last five years, EBIT Margin for VALN reached as high as 208.25% in Q1 2024 and fell as low as 184.92% in Q2 2022.
- A 5-year average of 43.93% and a median of 50.58% in 2022 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin jumped 73725 bps — and 2025, when it tumbled 22036 bps.
- Year by year, EBIT Margin stood at 50.58% in 2022, then fell by 18 bps to 59.45% in 2023, then jumped by 31 bps to 41.11% in 2024, then tumbled by 78 bps to 73.03% in 2025, then declined by 5 bps to 76.68% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 76.68%, 73.03%, and 169.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -76.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.68% |
| Dec 31, 2025 | -73.03% |
| Sep 30, 2025 | -169.96% |
| Jun 30, 2025 | -22.49% |
| Mar 31, 2025 | -12.11% |
| Dec 31, 2024 | -41.11% |
| Sep 30, 2024 | -29.86% |
| Jun 30, 2024 | -56.61% |
| Mar 31, 2024 | 208.25% |
| Dec 31, 2023 | -59.45% |
| Sep 30, 2023 | -58.35% |
| Jun 30, 2023 | -45.71% |
| Mar 31, 2023 | -49.46% |
| Dec 31, 2022 | -50.58% |
| Sep 30, 2022 | 59.56% |
| Jun 30, 2022 | -184.92% |
| Mar 31, 2022 | -84.32% |
| Dec 31, 2021 | 63.33% |
| Sep 30, 2021 | -677.70% |
| Jun 30, 2021 | -226.60% |